Clinical Scorecard: Long-lasting remission achieved after limited-duration bispecific antibody treatment in individuals with relapsed/refractory multiple myeloma
At a Glance
Category
Detail
Condition
Relapsed/refractory multiple myeloma
Key Mechanisms
Bispecific antibodies targeting BCMA and GPRC5D engage T-cells to induce deep and durable anti-myeloma responses
Target Population
Patients with relapsed/refractory multiple myeloma after multiple prior lines of therapy
Care Setting
Academic medical centers and clinical trial settings
Key Highlights
Bispecific antibodies teclistamab, elranatamab (BCMA-targeting) and talquetamab (GPRC5D-targeting) show 57–71% response rates in relapsed/refractory MM.
Fixed-duration bispecific antibody treatment with treatment-free intervals may reduce T-cell exhaustion, relapse mechanisms, infection risk, and treatment burden.
In a retrospective cohort of 23 patients discontinuing bsAb for reasons other than progression, over 80% remained progression-free at 1 year.
Guideline-Based Recommendations
Diagnosis
Identify relapsed/refractory multiple myeloma patients with prior lines of therapy and assess cytogenetic risk by FISH.
Management
Use FDA-approved bispecific antibodies (teclistamab, elranatamab, talquetamab) targeting BCMA or GPRC5D in patients with ≥4 prior therapies.
Consider fixed-duration dosing strategies to mitigate T-cell exhaustion and reduce infection-related morbidity.
Monitor for and manage infections, neutropenia, and other toxicities that may necessitate treatment discontinuation.
Monitoring & Follow-up
Regularly assess treatment response (VGPR or better) and monitor for relapse post-treatment discontinuation.
Monitor immune function and infection rates, especially with prolonged bsAb exposure.
Follow progression-free survival and overall survival longitudinally after treatment cessation.
Risks
Continuous bsAb exposure may cause T-cell exhaustion reducing efficacy of subsequent therapies.
Higher incidence of BCMA gene mutations or loss after bsAb therapy compared to CAR T-cell therapy.
Increased risk of severe infections correlating with duration of bsAb treatment.
Potential for second malignancies and other adverse events leading to treatment discontinuation.
Patient & Prescribing Data
Heavily pre-treated relapsed/refractory multiple myeloma patients with median 4 prior therapies, including autologous transplant recipients.
Patients achieving VGPR or better prior to bsAb discontinuation can maintain durable remission (>80% PFS at 1 year) after limited-duration therapy; infections are a common cause for stopping treatment.
Clinical Best Practices
Consider fixed-duration bispecific antibody treatment with planned treatment-free intervals to preserve T-cell function and reduce toxicity.
Closely monitor for infections and hematologic toxicities to guide treatment duration and dosing frequency adjustments.
Evaluate cytogenetic risk factors to inform prognosis and post-discontinuation surveillance.
Educate patients on adherence and promptly address adverse events to optimize outcomes.
Use multidisciplinary approaches in academic centers for managing complex relapsed/refractory MM cases receiving bsAb therapy.
